Cargando…

In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses

Although the prevalence of polymerase acidic (PA)/I38T strains of influenza virus with reduced susceptibility to baloxavir acid is low, there is a possibility of emergence under selective pressure. Furthermore, the virus may be transmitted between humans. We investigated the in vivo efficacy of balo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuroda, Takayuki, Fukao, Keita, Yoshida, Shinpei, Oka, Ryoko, Baba, Kaoru, Ando, Yoshinori, Taniguchi, Keiichi, Noshi, Takeshi, Shishido, Takao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222987/ https://www.ncbi.nlm.nih.gov/pubmed/37243240 http://dx.doi.org/10.3390/v15051154

Ejemplares similares

1343. Prophylactic Dosing of Baloxavir Acid Eliminates Mortality in Mice Lethal Influenza A Virus Infection Model
por: Shano, Shinya, et al.
Publicado: (2018)

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
por: Fukao, Keita, et al.
Publicado: (2019)

Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
por: Fukao, Keita, et al.
Publicado: (2023)

Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models
por: Fukao, Keita, et al.
Publicado: (2019)

Carryover effects of baloxavir acid in human nasopharyngeal/pharyngeal swabs on infectious titer testing of influenza virus
por: Baba, Keiko, et al.
Publicado: (2020)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
por: Taniguchi, Keiichi, et al.
Publicado: (2022)

Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model
por: Lee, Leo Y, et al.
Publicado: (2021)

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
por: Taniguchi, Keiichi, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection
por: Ando, Yoshinori, et al.
Publicado: (2020)

The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2020)

1350. Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2018)

Delayed Dosing of S-033188, a Novel Inhibitor of Influenza Virus Cap-dependent Endonuclease, Exhibited Significant Reduction of Viral Titer and Mortality in Mice Infected with Influenza A Virus
por: Fukao, Keita, et al.
Publicado: (2017)

Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model
por: Koszalka, Paulina, et al.
Publicado: (2022)

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)

Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil
por: Hashimoto, Takashi, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
por: Fukao, Keita, et al.
Publicado: (2023)

A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions
por: Koszalka, Paulina, et al.
Publicado: (2020)

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020)

A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid
por: Takizawa, Naoki, et al.
Publicado: (2022)

Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission
por: Lee, Leo Yi Yang, et al.
Publicado: (2020)

Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial
por: Portsmouth, Simon, et al.
Publicado: (2020)

Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil
por: Nakauchi, Mina, et al.
Publicado: (2020)

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)

97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant
por: Checkmahomed, Liva, et al.
Publicado: (2019)

LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
por: Ison, Michael G, et al.
Publicado: (2018)

Viral Fitness of Baloxavir-Resistant Recombinant Influenza B/Victoria- and B/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs
por: Saim-Mamoun, Amel, et al.
Publicado: (2023)

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019
por: Takashita, Emi, et al.
Publicado: (2019)

Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan
por: Hirotsu, Nobuo, et al.
Publicado: (2023)

Modeling mitigation of influenza epidemics by baloxavir
por: Du, Zhanwei, et al.
Publicado: (2020)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020)

Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study
por: Komeda, Takuji, et al.
Publicado: (2020)

A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023
por: Takashita, Emi, et al.
Publicado: (2023)

1645. Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time and Influenza Type B Virus Infection (CAPSTONE-1 Study)
por: Kawaguchi, Keiko, et al.
Publicado: (2018)

Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors
por: Jones, Jeremy C., et al.
Publicado: (2018)

Synergistic Antiviral Activity of S-033188/S-033447, a Novel Inhibitor of Influenza Virus Cap-Dependent Endonuclease, in Combination with Neuraminidase Inhibitors In Vitro
por: Kitano, Mitsutaka, et al.
Publicado: (2017)

Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020)

Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021)

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
por: Mishin, Vasiliy P., et al.
Publicado: (2019)

648. Baloxavir Resistance: qPCR Detection of Antiviral Resistance Markers in Influenza A Virus
por: Tyler, Aaron J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rncoj1mcffk07i50v5325tqgps